Cheshire, UK--(Marketwire - October 1, 2007) -

                             Protherics PLC



                      Notification of Director's Interests



London, UK; Brentwood, TN; 1 October 2007 - Protherics PLC ("Protherics" or the
"Company"), the international biopharmaceutical company focused on critical care
and cancer, today announces that, on 28 September 2007, in accordance with
paragraph 3.1.2 of the FSA Disclosure and Transparency Rules, the Company
received notification that, on 28 September 2007, Garry Watts, Non-executive
Director of Protherics, acquired 40,000 ordinary 2p shares in the Company ("
Ordinary Shares") at a price of 48.42 pence per share.



Following the above transaction, Mr. Watts holds a beneficial interest in 90,000
Ordinary Shares (0.026% of the issued ordinary share capital of the Company).
The Company's issued ordinary share capital is 339,316,822 shares.



                                   |  Ends  |







For further information please contact:


Protherics
Nick Staples, Director of Corporate Affairs           +44 (0) 7919  480510
Julie Vickers, Company Secretary                      +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, David Yates                       +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt               +1 212 850 5600



Or visit www.protherics.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END